MBFG09 Posted - 09/24/24

$PSTV for the end of the week …news… stay tune $AMLX $VTYX $CTIC

NVDAMillionaire Posted - 3 months ago

$CTIC CTI BioPharma Corp. (NASDAQ:CTIC): A Promising Oncology Player Poised for Growth http://beyondspx.com/2024/08/05/cti-biopharma-corp-nasdaqctic-a-promising-oncology-player-poised-for-growth/

frbdcsbjax Posted - 03/29/24

$CTIC anyone here?

CruBones Posted - 03/22/24

@cheetohottaki look at how $ctic behaved before buy out

pharmde Posted - 8 months ago

@spartaksus interesting to see $CTIC had 2 bidders. It was unfortunate that they only got bought after FDA approval and after a few months of sales only for a 2x gain. Maybe Mirati, but we are definitely not a Seagen

Micky11 Posted - 8 months ago

@bankrupt_bob @Gaucho12 should be no problem big short have seen it before with $CTIC bought out with 28M short last year. That's a good middlefinger to the shorts Ardelyx will be bought out one day .The news will happen suddenly if not now maybe next year.

AlexPEC Posted - 10 months ago

$ATYR The 900,000 $1.5 Employee Stock Option (right to buy) incentive acquired by CEO/CFO/GC is crazy, so affirmative to buyout or growth. Just like $CTIC buyout three months ago. But I rather love to grow with company gradually.

SoldTooSoon Posted - 11 months ago

@cobragene I messed up with $ctic had xx,xxx shares under $2, sold it around 4 should have held it for a year and would have been $8.... Lesson learned..

MRKR2025 Posted - 11 months ago

$IMGN $CTIC $MRTX $IOVA Never owned CTIC, owned MRTX way back when they were Canadian MethylGene, held and did well, owned IMGN and sold it at a loss and never bought back in so missed it all, waiting for IOVA to pay off Big Time.

Night_Owl_Biotech Posted - 11 months ago

The attachment documents the enterprise value & 10-year revenue estimates of $IOVA compared to the 3 oncology focused bios acquired in 2023 including $CTIC, $MRTX & $IMGN. It is interesting to note IOVA is expected to generate roughly the same revenue profile the first 5 years as IMGN that was just acquired for an enterprise value of $9.6Billion (of course IOVA may produce lower gross margins). In July 2023 institutional investors purchased ~$160MM worth of IOVA at $7.50/share. IOVA has a 2/24/24 PDUFA date for Lifileucel. If the FDA issues a CRL then IOVA could be worthless. We have no idea what will happen to IOVA's share price. Otherwise, as always do your own due diligence. We are simply sharing our observations & analysis.

Night_Owl_Biotech Posted - 11/30/23

@audi999999 @therealcaptainamerica Attached is a simple comparison of the $IOVA peer valuation related data points from the 3 most recent oncology focused M&A transactions. FY2027 & FY2028 consensus revenue estimates are per Seeking Alpha. If the data points are accurate, especially the patent related dates, then it suggests IOVA's Lifileucel is worth north of 3.6X FY2028 consensus revenue estimates (assuming patented through 2038) if approved & if revenue estimates are credible. $MRTX & $CTIC were acquired at 0.26X Year 5 consensus revenue estimates for each year of patent life remaining. It appears $IMGN is being acquired at 0.38X Year 5 assuming Elahere revenues if patented through 2043 as noted in their last 10K. Put simplest, simple analytics suggests the $IMGN acquisition is a very important valuation inflection point for IOVA should Lifileucel be approved. As always, we could be very wrong.

Night_Owl_Biotech Posted - 1 year ago

Our hypothetical/theoretical $IOVA valuation 2 years from now if; 1. Lifileucel is approved and if; 2. LN-145 continues to look like it will be approved and if; 3. IOVA FY2030 consensus revenue estimates are more or less unchanged and if; 4. Our patent date assumptions are accurate and if; 5. IOVA is acquired at $MRTX & $CTIC 5-year multiples per year to LOE. 6. 3 other things happen as noted in the video We're not suggesting investing in IOVA. This is not investment advice. It is as likely IOVA will fail. We've been very wrong before. IOVA could go bankrupt. We're only sharing a hypothetical w Good luck. https://www.youtube.com/watch?v=o5WPL2vlvSs

Night_Owl_Biotech Posted - 1 year ago

Our new YouTube video (link below) calculates the theoretical market cap of $BCRX if it were to be acquired today at revenue multiples consistent with the $MRTX & $CTIC acquisitions. BCRX has gross margins @ 99% (on par with MRTX/CTIC). The video is for entertainment purposes only. We do not recommend you buy or sell any particular stock as we have no idea how a particular company nor the markets as a whole will trade in the future. Also, the video is dated 11/6/23 & the data presented is unaudited. Do not rely on our analysis. https://www.youtube.com/watch?v=Dv20cxqhcdc&feature=youtu.be

TrendyChart Posted - 10/26/23

Upcoming Earnings Report: $CTIC CTI BioPharma will be reporting on 11/06/2023 at 4:00PM | Do you have a rosy or gloomy earnings perspective for this stock?

tickeron Posted - 1 year ago

$CTIC vs. $MNKD: which stock is the best to buy? #CTIBioPharma https://srnk.us/go/4865350

tickeron Posted - 1 year ago

$CTIC vs. $MNKD: what will be the best investment? #CTIBioPharma https://srnk.us/go/4864095

tickeron Posted - 1 year ago

How to make the right investment? Compare $CTIC vs. $MNKD. #CTIBioPharma https://srnk.us/go/4863305

tickeron Posted - 1 year ago

What stocks might make more money? Compare $CTIC vs. $MNKD. #CTIBioPharma https://srnk.us/go/4862418

macroaxis Posted - 1 year ago

CTi Biopharma ( $CTIC ) buy or sell recommendation is NOT RATED https://www.macroaxis.com/stock/CTIC/CTi-Biopharma-Corp #stocks #news #wallstreet

tickeron Posted - 1 year ago

$CTIC vs. $MNKD: what is the best stock to add to your portfolio? #CTIBioPharma https://srnk.us/go/4861101

tickeron Posted - 1 year ago

If you have $CTIC or $MNKD in your portfolio, pay attention! #CTIBioPharma https://srnk.us/go/4860188

macroaxis Posted - 1 year ago

CTi Biopharma ( $CTIC ) buy or sell recommendation is NOT RATED https://www.macroaxis.com/stock/CTIC/CTi-Biopharma-Corp

Night_Owl_Biotech Posted - 08/28/23

Would investors familiar with $TSVT review our attachment. We're trying to quantify downside risk to TSVT longer-term outside normal market, regulatory & mgmt competence risks. TSVT trades for less than their 6/30/23 cash & only slightly higher than cash minus all liabilities (excl the lease on their plant which is secured by their validated facility...which would certainly be assumed by any buyer in a M&A scenario). Since FDA approved products are worth a multiple of current/future sales then, in theory, TSVT's valuation ascribes no value to its 50% share of Abecma (LOE is not until 2036). Abecma FY22 sales = $300MM Recent peer M&A transactions ($CTIC $PRVB $GBT $CCXI) suggest products w/LOE in 28-31 are worth ~3X FY28 consensus revenue estimates. Using this metric, assuming 0% growth in Abecma sales thru 28, suggests Abecma is worth $450MM to an acquirer (nevermind the pipeline)? What are we missing? Thank you. As always, we could be very wrong.

MMAM21 Posted - 08/28/23

@OnlyOneLife81 @AvantGardeGroup but $CTIC buyout was about a year after approval

MMAM21 Posted - 08/28/23

@OnlyOneLife81 @AvantGardeGroup also similar to $CTIC, which soon after got bought by SOBI

tickeron Posted - 08/28/23

If you have $CTIC or $MNKD in your portfolio, pay attention! #CTIBioPharma https://srnk.us/go/4846911

zedma Posted - 08/27/23

@MBA_Certified yep, losers like you keep short selling, now short interest reached 23,351,239. I remember how short sellers on $CTIC were crying that acquisition price is overpriced 😂😂😂, as if they could do anything more.

TeddyBearKiller Posted - 08/26/23

@Observationalist been a while…How are things? Licked my wounds, bounced back with a $CTIC hit. This year has been meh so far…

nlrmandate Posted - 08/25/23

$TGTX maybe a bit off topic, but interesting read about alleged insider trading in connection with $CTIC buyout https://abovethelaw.com/2023/08/ex-attorney-at-top-10-biglaw-firm-charged-with-insider-trading/

Nostradamus191 Posted - 1 year ago

$TGTX time to silence you retail short bit#ches. I got in on $CLDX at 2.4. $CTIC at 2.09. $AXSM at 8. Have made a great life seeing asymmetric upside potential in biotechs. The time to buy and hold long is now. You shorts are holding a ticking time bomb. Tick.. tock